Athira Pharma Inc (NAS:ATHA)
$ 0.5499 0.0114 (2.12%) Market Cap: 21.26 Mil Enterprise Value: -46.72 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 36/100

Athira Pharma Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2023 / 06:30PM GMT
Release Date Price: $2.26 (-4.64%)
James Condulis
Stifel - Analyst

Good afternoon, everyone. Thanks for joining. It's a pleasure to be joined by the Athira executive team here. Maybe Mark, it makes sense to just give a background. And I know you have some slides here, so feel free to walk through as many as you want, and then we can jump into some Q&A.

Mark Litton
Athira Pharma, Inc. - President & CEO

Yes. Okay, James. Sure. Let's just first do some introductions about who we have on this call. I'm Mark Litton, the CEO of Athira. I'm joined by our CMO, Hans Moebius; and I'm also joined by our CSO, Kevin Church. So many, many thanks for having us on this panel, fireside chat. Let me give you a little brief overview of who we are and then we can sort of jump into the questions.

So Athira is a late-stage clinical development company focused on repairing and protecting and restoring neuronal health. Our platform approach starts from enhancing a naturally occurring repair mechanism, the HGF system that our bodies use every day to protect, repair our nervous system. And there's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot